Bioasis Technologies

Bioasis Technologies Gross Margin

The Gross Margin of Bioasis Technologies (BIOAF) as of Oct 20, 2026 is 100.00 %. In the previous year, Gross Margin was 99.27 % — a change of 0.74% (higher).

Gross Margin

100.00 %

YoY

0.74%

Last updated:

Gross Margin of Bioasis Technologies is 2020 100.00 % . Gross Margin of Bioasis Technologies was 2019 99.27 % . It decreases by 0.74% higher compared to the previous year.

Bioasis Technologies's gross margin stands at 100.0%, up from -14.8% several years earlier.

The Bioasis Technologies Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2016
-14.82 CAD
Jan 1, 2017
16.20 CAD
Jan 1, 2018
20.68 CAD
Jan 1, 2019
99.27 CAD
Jan 1, 2020
100.00 CAD
The Bioasis Technologies Gross Margin history
YEARGross MarginYoY
100.00 %+0.74%
99.27 %+379.91%
20.68 %+27.69%
16.20 %-209.31%
-14.82 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioasis Technologies Stock analysis

What does Bioasis Technologies do? biOasis Technologies, Inc. generates revenue by developing therapeutics using its proprietary xB3 platform, which is designed to deliver treatments across the blood brain barrier for central nervous system disorders. The company focuses on areas of high unmet medical need, specifically targeting brain cancers and neurodegenerative diseases. This technology leverages a human transport protein found circulating at low levels in the blood to shuttle molecules to their targets within the brain via receptor-mediated transcytosis. The firm markets its in-house development programs aimed at creating both symptomatic and disease-modifying treatments for brain-related diseases and disorders. By utilizing the xB3 platform, biOasis Technologies, Inc. addresses specific therapeutic challenges in the central nervous system, offering solutions for conditions that currently lack adequate medical interventions. The business model relies on the efficacy of this delivery system to reach targets within the brain, serving the needs of patients suffering from these severe neurological conditions. Bioasis Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioasis Technologies stock

Gross Margin of Bioasis Technologies is 100.00 % in 2020.

Gross Margin of Bioasis Technologies changed from 99.27 % to 100.00 %, representing a 0.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Bioasis Technologies since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Bioasis Technologies with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Bioasis Technologies

All Key Metrics — Bioasis Technologies